Article ; Online: Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai Health System COVID-19 patients.
2021 Volume 16, Issue 7, Page(s) e0253660
Abstract: ... comorbidities and sequelae along with peripheral blood biomarkers that were associated with elevated clinical ... identified Mount Sinai Health System COVID-19 database. We assessed the risk of mortality based ... severity and poor outcomes in COVID-19 patients. Overall, these findings detail the granularity ...
| Abstract | With the continuing rise of SARS-CoV2 infection globally and the emergence of various waves in different countries, understanding characteristics of susceptibility to infection, clinical severity, and outcomes remain vital. In this retrospective study, data was extracted for 39,539 patients from the de-identified Mount Sinai Health System COVID-19 database. We assessed the risk of mortality based on the presence of comorbidities and organ-specific sequelae in 7,032 CoV2 positive (+) patients. Prevalence of cardiovascular and metabolic comorbidities was high among SARS-CoV2+ individuals. Diabetes, obesity, coronary artery disease, hypertension, atrial fibrillation, and heart failure all increased overall mortality risk, while asthma did not. Ethnicity modified the risk of mortality associated with these comorbidities. With regards to secondary complications in the setting of infection, individuals with acute kidney injury and acute myocardial injury showed an increase in mortality risk. Cerebral infarcts and acute venous thromboembolic events were not associated with increased risk of mortality. Biomarkers for cardiovascular injury, coagulation, and inflammation were compared between deceased and survived individuals. We found that cardiac and coagulation biomarkers were elevated and fell beyond normal range more often in deceased patients. Several, but not all, inflammatory markers evaluated were increased in deceased patients. In summary, we identified comorbidities and sequelae along with peripheral blood biomarkers that were associated with elevated clinical severity and poor outcomes in COVID-19 patients. Overall, these findings detail the granularity of previously reported factors which may impact susceptibility, clinical severity, and mortality during the course of COVID-19 disease. |
|---|---|
| MeSH term(s) | Biomarkers/blood ; COVID-19/mortality ; COVID-19/pathology ; COVID-19/virology ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/ethnology ; Comorbidity ; Databases, Factual ; Diabetes Mellitus/epidemiology ; Diabetes Mellitus/ethnology ; Humans ; Prevalence ; RNA, Viral/analysis ; Real-Time Polymerase Chain Reaction ; Retrospective Studies ; Risk Factors ; SARS-CoV-2/genetics ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Survival Analysis |
| Chemical Substances | Biomarkers ; RNA, Viral |
| Language | English |
| Publishing date | 2021-07-06 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S. |
| ZDB-ID | 2267670-3 |
| ISSN | 1932-6203 ; 1932-6203 |
| ISSN (online) | 1932-6203 |
| ISSN | 1932-6203 |
| DOI | 10.1371/journal.pone.0253660 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.